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INTRODUCTION
Szabó & Gellen1 were the first to report a
relationship between accumulated fetal nuchal
fluid and fetal abnormalities. They observed
105 normal karyotype fetuses and found more
than 3 mm of nuchal fluid accumulated in 7
fetuses with trisomy 21 and in one normal
karyotype fetus.
In 1992, Nicolaides et al.2 introduced the
new term “nuchal translucency (NT)” which
was defined as the thickness of the translucent
space between the skin and the soft tissue over-
lying the fetus cervical spine, measured in
millimeters and tenths of a millimeter via ul-
trasound. This study was performed in a high-
risk population sample, at 10 weeks to 14
weeks pregnant. The NT measures considered
abnormal were 3 mm and above and with 64%
sensitivity for trisomy 21.
The etiology for this nuchal fluid accu-
mulation has still not been defined and vari-
ous theories offer an explanation. The most
cited are: deficient and transitory lymphatic
drainage of the cervical region due to disor-
ders in the lymphatic connections,3,4 exces-
sive perfusion of the protective mechanism
of the central nervous system as a result of
the rapid growth of the initial placenta which
consequently increases the circulatory vol-
ume5 and cardiac alterations - mainly the nar-
rowing of the aortic isthmus and conse-
quently increasing the vascular flow of the
fetal cervical region.6,7
Many authors8-17 have published studies
showing that an increase in the nuchal thick-
ness measured in the first and at the begin-
ning of the second trimester of pregnancy is
associated with greater prevalence of fetal aneu-
ploidy. The sensitivity of these publications
with different cutoff points varies from 20%
to 93.5%.
Some publications consider NT ³ 2.5
mm18,19 as positive screening values, whereas
the great majority use a fixed value of -
NT ³ 3 mm.2,10,15,20,21,22
The Harris Birthright Research Centre for
Fetal Medicine has coordinated the largest
study to assess NT accuracy. It was conducted
at 22 ultrasound centers in England on 96,127
women who were 10 weeks to 14 weeks preg-
nant. The risk for trisomy 21 was calculated
by multiplying the NT probability ratio by the
prevalence of this trisomy at different mater-
nal and gestational ages. The test was positive
for 5% of the population which included 77%
of the trisomy 21 cases.23 This study consid-
ered the patient’s age as well as the gestational
age and used a software program to calculate
the risk for trisomy 21.
The aim of this study was to define the
best fixed cutoff point for nuchal translucency,
with the assistance of the receiver operator
characteristic curve (ROC curve),24 and the
accuracy of this cutoff for all fetal aneuploidy
screening and for trisomy of chromosome 21
in a South American population.
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METHODS
The study was submitted for assessment
to the Research Ethics Committee of the State
University of Campinas (UNICAMP) and was
approved.
This was a diagnostic validation study. The
sample size was estimated using Schäfer’s24
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CONTEXT: The literature shows an association between
several ultrasound markers and chromosome abnor-
mality. Among these, measurement of nuchal trans-
lucency has been indicated as a screening method
for aneuploidy. The trisomy of chromosome 21 has
been most evaluated.
OBJECTIVE: To define the best fixed cutoff point for nuchal
translucency, with the assistance of the ROC curve,
and its accuracy in screening all fetal aneuploidy
and trisomy 21 in a South American population.
TYPE OF STUDY: Validation of a diagnostic test.
SETTING: This study was carried out at the State Univer-
sity of Campinas, Campinas, Brazil.
PARTICIPANTS: 230 patients examined by ultrasound
at two tertiary-level private centers, at 10 to 14 weeks
of gestation.
DIAGNOSTIC TEST: The participants consisted of all
those patients who had undergone ultrasound
imaging at 10 to 14 weeks of gestation to measure
nuchal translucency and who had had the fetal or
neonatal karyotype identified.
MAIN MEASUREMENTS: Maternal age, gestational
age, nuchal translucency measurement, fetal or
neonatal karyotype.
RESULTS: Prevalence of chromosomal defects – 10%;
mean age – 35.8 years; mean gestational age –
12 weeks and 2 days; nuchal translucency (NT) thick-
ness – 2.18 mm. The best balance between sensitiv-
ity and specificity were values that were equal to or
higher than 2.5 mm for overall chromosomal ab-
normalities as well as for the isolated trisomy 21.
The sensitivity for overall chromosomal abnormali-
ties and trisomy 21 were 69.5% and 75%, respec-
tively, and the positive likelihood ratios were 5.5
and 5.0, respectively.
CONCLUSION: The measurement of nuchal translucency
was found to be fairly accurate as an ultrasound
marker for fetal abnormalities and measurements
equal to or higher than 2.5 mm were the best fixed
cutoff points.
KEY WORDS: Aneuploidy. Ultrasound. Chromosomes.
Fetus. Prenatal Diagnosis.
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Table 1. Distribution according
to karyotype fetus
Normal Affected
N % N %
Total 207 90 23 10
 Table 2. The Crown-Rump Length (CRL)
N Average (mm) *CI (95%) Minimum (mm) Maximum (mm)
Total 230 59.70 58.30 to 61.08 39.0 86.0
  *confidence interval.
Table 3. Nuchal translucency values
N Average (mm) *CI (95%) Minimum (mm) Maximum (mm)
Total 230 2.18 1.96 to 2.39 0.90 14.00
   *confidence interval.
method – a specific method for validation stud-
ies that uses the ROC curve assuming a 70%
sensitivity and 90% specificity.25 A minimum
of 217 participants were necessary.
The study included patients who had un-
dergone ultrasound imaging at tertiary level
private centers and who, according to the
crown-rump length (CRL),26 were at the stage
of between 10 and 14 weeks gestation, with a
single gestation and live fetus. Nuchal trans-
lucency was measured in all the cases and later,
Figure 1. Ultrasound image of the caliper method used for measuring nuchal translucency.
fetal karyotyping was carried out for indica-
tions that excluded abnormal NT.
Nuchal translucency was defined as the
thickness of the translucent space between the
skin and the soft tissues overlying the fetus cer-
vical spine, measured in millimeters and tenths
of a millimeter by ultrasound and following
the criteria set by the Fetal Medicine Founda-
tion 27 (Figure 1).
Five physicians certified by the London or
Brazilian Fetal Medicine Foundation measured
the CRL and NT using the Sequoia®, Aspen
128 X P 10 - Acuson® and Toshiba® SH 140
equipment. The ultrasound examination was
transvaginal or abdominal.
Chorionic villus biopsy, amniocentesis,
blood or placenta provided fetal cells for fetal
karyotyping.
A univariate descriptive analysis was con-
ducted and the sensitivity, specificity and the
nuchal translucency ratio were calculated for
normal or altered karyotype (the gold standard).
The ROC curve for the nuchal translu-
cency values was drawn in order obtain the
best cutoff point for this measure. Logistic re-
gression analysis was used to find out whether
the translucency value was a predictor for fe-
tal abnormalities. All the data used in this study
were obtained from the files of patients who
had previously undergone nuchal translucency
measurement and fetal karyotyping.
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RESULTS
The study included 230 patients. There
was a 10% prevalence of fetal abnormalities
(Table 1). The patients’ ages ranged from 21
years to 45 years – the mean age was 35.8 years.
The minimum crown-rump length of the fe-
tus (CRL) was 39 mm (which corresponds to
a 10-week gestational age) and its maximum
value was 86 mm (14 weeks gestational age).
The mean CRL was 59.7 mm (12 weeks and
2 days gestational age) (Table 2). The mean
value of nuchal translucency (NT) was 2.18
mm – the minimum value was 0.9 mm and
the maximum value was 14 mm (Table 3).
A higher frequency of normal karyotype
fetuses was observed when the NT values were
low and when the NT values were higher; the
frequency of aneuploidy was also higher (P <
0.01) (Table 4). The most frequent chromo-
somal abnormality was trisomy 21 followed
by trisomy 18 (Table 5).
The ROC curve (Figure 2) was drawn
based on the sensitivity and specificity values
and identified NT ³ 2.5 mm as a good bal-
ance between sensitivity and specificity for
screening aneuploidy. The measurement of NT
³ 2.5 mm helped to correctly classify 16 fe-
tuses out of 23 fetuses with chromosomal al-
terations and 181 fetus out of 207 normal
karyotype fetuses (Table 6). The ROC curve
also demonstrates that an NT measurement ³
2.5 mm gives a good balance between sensi-
tivity and specificity for screening trisomy 21
(Figure 3). Using the cut-off point of NT ³
2.5 mm (Table 7), 9 out of 12 fetuses with
trisomy 21 (75% sensitivity) and 185 out of
218 normal fetuses (84.9% specificity, 5.0 like-
lihood ratio) were correctly classified.
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DISCUSSION
This study proved that nuchal translucency
at 10 to 14 weeks gestation was useful for
screening general chromosomal abnormalities
as well for specific trisomy 21 screening.
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The mean age of the women in this study
was 35.8 years. This age group showed a high
risk for aneuploidy and, as such, this fact may
have positively influenced the accuracy of the
test. There can be two explanations for the
10% aneuploidy prevalence – the women’s age
and a concentration of high risk cases at the
two clinics, which were Fetal Medicine refer-
ral centers.
The tendency tests used showed that the
NT measurement for normal fetuses was lower
than that for fetuses that had chromosomal ab-
normalities. This was in keeping with the data
in the literature10,17,19,28-32 and reinforced the use
of the NT measure for screening aneuploidy.
The ROC curve helped define the best cut-
off point for the NT measurement at ³ 2.5
mm18,19 for all aneuploidy. Some other studies
have also obtained the same NT value, but a
greater number of research studies have fixed
the value as NT ³ 3 mm.2,10,15,20-22
When the NT measurement ³ 2.5 mm,
all the aneuploidy showed a 69.5% sensitivity,
87.4% specificity and 5.5 likelihood ratio.
These results coincided with the 65% sensi-
tivity obtained by Hafner et al.19b in a 0.4%
aneuploidy population and also with the re-
sults of Pandya et al.18 - 75% sensitivity and
0.2% aneuploidy.
The most frequent chromosomal altera-
tion was trisomy 21 (12 cases) followed by tri-
somy 18 (5 cases), and in 3 cases the chromo-
some X monosomy, one of which was a case
of mosaicism. Trisomy 21 is also the most fre-
quent occurrence in the literature. In neonates,
its frequency of identification is tenfold when
compared to trisomy 18,33 and as in this study,
three times more frequent in 9 to 14 week
gestations.34 In the literature, the frequency of
the X monosomy is 1.5% of all recognized
gestations, although only 1% of these survive
beyond the 28th gestational week. The propor-
tions of trisomy 21, trisomy 18 and X
monosomy were similar to those found by
Snijders et al.23 in 1998.
The largest collaborative study published
to date on nuchal translucency consisted of
96,127 patients, used sequential risk, and its
accuracy for trisomy 21 is better than that
found in this study (82.2%). However, soft-
ware is needed to classify the positively and
negatively screened cases. Probably the reason
for the high accuracy of this large collabora-
tive study by Snijders is that it took into ac-
count the risk related to gestational age, ma-
ternal age and the nuchal translucency meas-
ure when calculating sequential risk.
The criteria for sample selection had the
aim of reducing the verification bias36 by in-
Table 7. Fetuses with trisomy 21 and those
without, according to the chosen cutoff point
Present (n) Absent (n)
TN ³ 2.5 9 33
TN < 2.5 3 185
Total 12 218
Sensitivity = 75.0 %; Specificity = 84.9 %; Positive likelihood ratio 5.0.
Table 6. Altered fetal karyotype and normal
karyotype - proportion at the chosen cutoff point
Altered Normal
TN ³ 2.5 16 26
TN < 2.5 7 181
Total 23 207
Sensitivity = 69.5%; Specificity = 87.4%; Positive likelihood ratio = 5.5.
Table 5. Maternal age, gestational age (GI), nuchal translucency (NT)
and fetal karyotype with aneuploidies
Case number Maternal age (years) GA  (weeks) NT (mm) Karyotype
1 26 11 weeks 1.0 47,XY,+21
2 26 11 weeks and 4 days 1.7 69,XXY
3 34 14 weeks 1.8 92,XXYY
4 41 13 weeks and 4 days 1.8 46,XX /45,X0
5 36 12 weeks and 5 days 1.8 47,XY,+21
6 37 12 weeks and 5 days 1.8 47,XY,+18
7 42 12 weeks 2.0 47,XY,+21
8 34 12 weeks and 4 days 2.5 47,XY,+21
9 41 11 weeks and 6 days 2.5 47,XX,+18
10 42 12 weeks and 4 days 3.0 47,XY,+18
11 38 11 weeks and 3 days 3.8 47,XX,+21
12 41 12 weeks 4.5 47,XX,+7
13 41 11 weeks and 6 days 4.8 47,XY,+21
14 38 13 weeks and 5 days 5.1 47,XY,+21
15 30 11 weeks and 2 days 5.3 47,XY,+21
16 38 11 weeks and 1 day 6.9 45,X0
17 42 12 weeks 7.2 47,XX+21
18 25 13 weeks and 5 days 7.7 47,XX,+21
19 38 12 weeks and 3 days 8.8 47,XX,+21
20 37 11 weeks and 2 days 9.4 47,XX+18
21 41 13 weeks and 5 days 10.0 47,XY,+21
22 26 13 weeks and 6 days 12.0 45,X0
23 43 13 weeks and 5 days 14.0 47,XY,+18
Table 4. Fetal karyotype
according to nuchal translucency
              Normal                 Affected
Translucency (mm) n % n %
< 1 3 1.5 0 -
1.0ú¾1.5 50 24.1 1 4.3
1.5ú¾2 94 45.5 5 21.8
2.0ú¾2.5 34 16.5 1 4.3
2.5ú¾3.0 14 6.7 2 8.7
3.0ú¾4.0 9  4.3 2 8.7
4.0ú¾5.0 1  0.5 2 8.7
5.0ú¾10.0 2 0.9 7 30.5
10 or more 0 - 3 13.0
Total 207 100.0 23 100.0
Cochran-Armitage tendency test: P < 0.01.
cluding in the study only those cases where the
indication had not been an increased NT but
the karyotype as a definite diagnosis. However,
the number of cases where the indication for
fetal karyotype was unknown was high. Maybe
the fetal karyotype was studied in these cases
because the NT measure was high.
Studies published with large samples have
used NT as an indication of fetal karyotype
and karyotype for high risk patients only (ad-
vanced maternal age, previous malformations),
whereas the assessment of the perinatal phe-
notype has been reserved for only low risk cases
and low NT.2,10,15,18-23
The abortion rate is higher when the fetal
NT is high and chromosomal abnormalities
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are present.37 Therefore, the neonate pheno-
type assessment may have underestimated the
number of fetuses, at 10 to 14 weeks, with
chromosomal abnormalities that were nor-
mally aborted later, and overestimated the sen-
sitivity test described by Pajkrt et al,17 leading
to biased verification as highlighted by Begg
& McNeil.36
In this study, an increase in fetal nuchal
translucency, at 10 to 14 weeks’ gestation,
showed a relationship with increased chromo-
somal alterations and was therefore useful in
screening overall or individual chromosomal
abnormalities. The accuracy was best for tri-
somy 21.
An important fact to be kept in mind is
that the sample size for this study was calcu-
lated for overall chromosomal abnormalities and
that an individualized analysis of the results for
trisomy 21 would possibly have a statistical
power inferior to that initially obtained.
The fact that this study analyzed a sample
with a high risk for aneuploidy should be un-
derscored, as it raised the accuracy of the screen-
ing tests. Consequently, this accuracy cannot
be generalized for populations where the initial
risk related to age and obstetric variables is
smaller. It has been found that in neonates,
polyploidy is extremely rare and that 30% of
the fetuses with trisomy 21, 80% of those with
trisomy 18, and nearly 99% of those with X
monosomy are spontaneously aborted or evolve
to death by 40 weeks of gestation.35,38 If these
rates were applied to this study and the maxi-
mum loss rate for each aneuploidy was accepted,
the NT screening would have identified 8 cases
of fetal trisomy, 21 live births, 1 case of trisomy
18 and no cases of polyploidy or monosomy X.
In countries where abortion in legally al-
lowed when chromosomal abnormalities are
identified, research on screening tests is focused
on trisomy 21 because of its low lethality.
In Brazil, the law does not provide for preg-
nancy interruption when chromosomal abnor-
malities are identified. However, a considerable
number of these fetuses have had cardiac mal-
formations or other defects in addition to aneu-
ploidy, which can turn the gestational progno-
sis poor. The recognition of these fetuses with
aneuploidy allows more specific examinations,
1. Szabo J, Gellen J. Nuchal fluid accumulation in trisomy 21 de-
tected by vaginosonography in first trimester. Lancet 1990;3:1133.
2. Nicolaides KH, Azar G, Byrne, D, Mansur C, Marks K. Fetal
nuchal translucency: ultrasound screening for chromosomal de-
fects in first trimester of pregnancy. Br Med J 1992;304:867-9.
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Figure 2. Balance between NT sensitivity and specificity to screen all chromosomal abnormalities
at different cutoff points of Receiver Operator Characteristic Curve (ROC).
such as fetal echocardiography and morphologi-
cal ultrasound, that will assist in the risk classi-
fication of these fetuses, thereby allowing pre-
natal programs and delivery in tertiary services
to be prepared to receive them. From a psycho-
logical point of view, screening and posterior
diagnosis gives the couple the possibility of
knowing the risks in the gestation and being
ready for unfavorable situations, and it also helps
to make them aware of the risks they face
regarding future gestations.
In this study, the measurement of nuchal
translucency demonstrated a high level of ac-
curacy for a population that had a high preva-
lence of aneuploidy, and therefore it can be in-
dicated in the same kind of circumstances.
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CONCLUSION
The measurement of nuchal translucency
in a South American population showed a high
degree of accuracy in screening overall chromo-
somal abnormalities and even higher accuracy
for trisomy 21. The best cutoff point obtained
for nuchal translucency was values ³ 2.5 mm.
Figure 3. Balance between NT sensitivity and specificity for trisomy 21 at different cutoff points
of Receiver Operator Characteristic Curve (ROC).
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CONTEXTO: A literatura mostra uma associação
entre diversos marcadores ultra-sonográficos e
riscos de cromossomopatias. Dentre os
marcadores ultra-sonográficos, a medida da
translucência nucal têm sido apontada como um
método de rastreamento de aneuploidias, sendo
a trissomia do cromossomo 21 a mais investigada.
OBJETIVO: Definir, com auxilio da curva ROC, o
melhor ponto de corte fixo da translucência
nucal e sua acurácia no rastreamento das
aneuploidias fetais como um todo, e para a
trissomia do cromossomo 21 numa população
sul americana.
TIPO DE ESTUDO: Validação de teste
diagnóstico.
LOCAL: O estudo foi realizado na Universidade
Estadual de Campinas, Campinas, Brasil.
PARTICIPANTES: 230 pacientes que realizaram
ultra-sonografia em dois centros privados de nível
terciário, entre 10 e 14 semanas de gestação.
PROCEDIMENTOS: Foram incluídas as pacientes
que realizaram ultra-sonografia, entre 10 e 14
semanas de gestação, onde se mediu a
translucência nucal, e a pesquisa do cariótipo
fetal ou do recém-nascido.
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RESUMO
VARIÁVEIS ESTUDADAS: Idade materna, idade
gestacional, medida da translucência nucal e
resultado do cariótipo fetal ou do recém-nascido.
RESULTADOS: A prevalência de cromossomopatias
foi de 10%. A idade média das pacientes foi de
35,8 anos. A idade gestacional média foi de 12
semanas e dois dias. A medida da translucência
nucal (TN) apresentou uma média de 2,18 mm.
O ponto de corte fixo, com melhor equilíbrio
entre sensibilidade e especificidade, foram os
valores iguais ou maiores que 2,5 mm para todas
as cromossomopatias e, também, para a trissomia
do cromossomo 21 isoladamente. A
sensibilidade do teste foi de 69,5% e 75% para
todas as cromossomopatias e para a trissomia
do cromossomo 21 respectivamente, com uma
razão de verossimilhança positiva de 5,5 e 5,0
para todas as cromossomopatias e para a
trissomia do cromossomo 21 respectivamente.
CONCLUSÕES: A medida translucência nucal
mostrou boa acurácia como marcador ultra-
sonográfico de cromossomopatias fetais, sendo
o valor de 2,5 mm o melhor ponto de corte fixo.
PALAVRAS-CHAVE: Aneuplodia. Ultra-sonografia.
Cromossomos. Feto. Diagnóstico pré-natal.
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